Hansa Biopharma AB (HNSA) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.253x

Based on the latest financial reports, Hansa Biopharma AB (HNSA) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-111.70 Million ≈ $-12.02 Million USD) by net assets (Skr-441.06 Million ≈ $-47.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HNSA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Hansa Biopharma AB - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Hansa Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hansa Biopharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hansa Biopharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
RFG Holdings Ltd JSE:RFG	0.121x
Kambi Group Plc F:7KB	0.089x
Xiangyang BOYA Precision Industrial Equipments Co. Ltd SHE:300971	0.044x
Telos Corp NASDAQ:TLS	0.083x
Guangdong Jushen Logistics Co Ltd SHE:001202	-0.042x
NWTN Inc. Class B Ordinary Shares NASDAQ:NWTN	0.062x
Hanwha Galleria Corp. KO:452260	N/A
KNOT Offshore Partners LP NYSE:KNOP	0.068x

Annual Cash Flow Conversion Efficiency for Hansa Biopharma AB (2008–2024)

The table below shows the annual cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see HNSA market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr-589.83 Million ≈ $-63.48 Million	Skr-674.88 Million ≈ $-72.63 Million	1.144x	-74.58%
2023-12-31	Skr-167.88 Million ≈ $-18.07 Million	Skr-755.65 Million ≈ $-81.32 Million	4.501x	+639.82%
2022-12-31	Skr602.91 Million ≈ $64.88 Million	Skr-502.73 Million ≈ $-54.10 Million	-0.834x	-31.28%
2021-12-31	Skr757.57 Million ≈ $81.53 Million	Skr-481.17 Million ≈ $-51.78 Million	-0.635x	-171.79%
2020-12-31	Skr1.24 Billion ≈ $133.67 Million	Skr-290.27 Million ≈ $-31.24 Million	-0.234x	+60.71%
2019-12-31	Skr562.82 Million ≈ $60.57 Million	Skr-334.77 Million ≈ $-36.03 Million	-0.595x	-150.04%
2018-12-31	Skr859.88 Million ≈ $92.54 Million	Skr-204.56 Million ≈ $-22.01 Million	-0.238x	+0.05%
2017-12-31	Skr630.66 Million ≈ $67.87 Million	Skr-150.10 Million ≈ $-16.15 Million	-0.238x	+28.60%
2016-12-31	Skr283.69 Million ≈ $30.53 Million	Skr-94.56 Million ≈ $-10.18 Million	-0.333x	-21.99%
2015-12-31	Skr211.53 Million ≈ $22.76 Million	Skr-57.80 Million ≈ $-6.22 Million	-0.273x	+42.39%
2014-12-31	Skr49.80 Million ≈ $5.36 Million	Skr-23.62 Million ≈ $-2.54 Million	-0.474x	-45.75%
2013-12-31	Skr45.68 Million ≈ $4.92 Million	Skr-14.87 Million ≈ $-1.60 Million	-0.325x	+0.26%
2012-12-31	Skr63.24 Million ≈ $6.81 Million	Skr-20.63 Million ≈ $-2.22 Million	-0.326x	+58.28%
2011-12-31	Skr34.71 Million ≈ $3.74 Million	Skr-27.14 Million ≈ $-2.92 Million	-0.782x	-39.01%
2010-12-31	Skr32.17 Million ≈ $3.46 Million	Skr-18.09 Million ≈ $-1.95 Million	-0.563x	-1.64%
2009-12-31	Skr24.92 Million ≈ $2.68 Million	Skr-13.79 Million ≈ $-1.48 Million	-0.553x	-44.73%
2008-12-31	Skr40.73 Million ≈ $4.38 Million	Skr-15.58 Million ≈ $-1.68 Million	-0.382x	--

About Hansa Biopharma AB

ST:HNSA Sweden Biotechnology

Market Cap

$345.79 Million

Skr3.21 Billion SEK

Market Cap Rank

#14260 Global

#225 in Sweden

Share Price

Skr32.22

Change (1 day)

+0.37%

52-Week Range

Skr23.76 - Skr42.74

All Time High

Skr348.00